{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54","upperLimit":"92","value":"76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Response rate is defined as the percentage of participants who have either a complete response (CR) or partial response (PR) for primary effusion lymphoma treated with etoposide phosphate, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R2) measured by the International Working Group Response Criteria for Malignant Lymphomas. Complete response (CR) is complete disappearance of all detectable evidence of disease. Partial response (PR) is at least a ≥50% decrease in the sum of the product of the diameters of up to 6 of the largest dominant nodes or nodal masses.","dispersionType":"90% Confidence Interval","groups":[{"description":"Cohort 1, Dose Level 1 - Lenalidomide 25mg by mouth (PO) was given on days 1 to 10, plus, etoposide phosphate, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). During cycle 1, Etoposide 50mg/m\\^2/day, Vincristine 0.4 mg/m\\^2 /day, and Doxorubicin 10 mg /m\\^2/day were given as continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide, Vincristine 0.4 mg/m\\^2 /day, and Doxorubicin were given as continuous intravenous infusion days 1 to 4. During cycles 2-6, doses of etoposide and doxorubicin were adjusted based on hematologic parameters during the previous cycle. During cycle 1, Prednisone 60 mg/m\\^2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m\\^2 /day PO days 1-5. During cycle 1, Cyclophosphamide 750 mg/m\\^2 was given on day 10. During cycles 2-6, Cyclophosphamide 750 mg/m\\^2 was given on day 5. Rituximab was administered on day 4 prior to the start of EPOCH during cycle 1 and on day 1 during cycles 2 to 6.","id":"OG000","title":"Lenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Response rate was calculated at the end of treatment (18 weeks of treatment)","title":"Response Rate for Primary Effusion Lymphoma Reported Using a 90% Confidence Interval","type":"SECONDARY","unitOfMeasure":"percentage of participants"}